Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
A phase 1/2 trial of AK119 in advanced solid tumours, run by Akeso, now recruiting.
Overview
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05689853 by Akeso, with 87 participants planned, started 2023-04-14 and due to reach its primary completion in 2026-12. Interventions recorded: AK119 and AK112.
Similar pages
not linked directly; found by shared links- TrialA Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
Shares Akeso and the tag pipeline.
- TrialA Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Shares Akeso and the tag pipeline.
- TrialA Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Shares Akeso and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.